Ann: AGM Chair's address and CEO's presentation, page-28

There was none....

It was suggested to me via email dated 27/11/24 from investor relations that the company had been clear throughout 2023/2024 that the AZD agreements were not active and no longer considered material to the business.......

I think that SPL has blended the definition of active 'clinical trial' and active 'agreement'.

My thoughts have always been that yes, the AZD0466 trial had ceased in July 2023, but the partnership agreement was still in place and that a new trial or collaboration was always a distinct possibility... Alas this was never the case and we have been in the dark until that little tidbit of info was communicated to us in the AGM slide figure......